Clinical Trial Update: Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy of vonoprazan (TAK-438) versus placebo for non-erosive gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• TAK-438 (vonoprazan) (vonoprazan)

Snippet

Sponsor: Takeda | Conditions: Non-erosive Gastroesophageal Reflux Disease | Phase 3 | Status: COMPLETED